Kazia Therapeutics Ltd ADR
Price & Volume
Stats
See more52W Range | $1.68-$15.80 |
Market Cap | $7.8M |
Shares Short | 16,783 |
Financials
See moreRevenue (12 Mos) | $560 |
Revenue Growth (YoY) | 35.6% |
Gross Profit (12 Mos) | $555 |
Diluted EPS | -$6.32 |
News
See moreYahoo Finance • 2 years ago
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Yahoo Finance • 2 years ago
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
Yahoo Finance • 2 years ago
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares
Yahoo Finance • 2 years ago
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
About
CEO | Dr. John Edwin Friend II, M.D. |
Address | Three International Towers, Sydney, NSW, Australia, 2000 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 0 |
